Effect of Mg-Orotate administration on cardiocirculatory Performance, the muscular concentration of phosphocreatine and the adaptation of muscle cellular level: A double blind, randomized, placebo-controlled, cross-over pilot study active ingredients versus placebo for 3 months

Wörwag Pharma GmbH & Co. KG0 个研究点目标入组 12 人开始时间: 2015年4月14日最近更新: 2018年4月30日

试验速览

暂无简介。

•1. Potential volunteer are obliged to be informed in details about the study and the loading results. In the study only included, who afterword signs a dated consent form.
•2. Men between 18 and 35 years, which may have a regular workout.
•3. No serious internal medical or neurological pre-existing diseases in the history (as judged by the investigator).
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 12
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•1. Chronic neurological or internal diseases.
•2. Taking medications or food supplements and vitamins within the last 4 weeks.
•3. Contraindications for the administration of magnesium orotate (e.g. allergy).
•4. Contraindications for the application of local anesthetics (allergy, Hypersensitivity).
•5. Participation in a drug trial within the last three months prior to study inclusion.
•6. Clinically significant deviation of certain laboratory parameters (Hb <13 g / dl, Deviation of the liver values over twice the normal (ALT, AST, ALP), GFR <60 ml / min, serum electrolytes (Na, K, Mg) in the normal. PT / PTT value outside the normal.
•7. Known coagulation disorders.
•8. Taking drugs.
•9. Venous conditions that do not allow multiple blood draws.

发起方